Abbreviated Impactor Measurement (AIM) Equipment

The Abbreviated Impactor Measurement (AIM) method provides a more efficient alternative to full-resolution cascade impactor testing for aerodynamic particle size distribution (APSD). AIM offers a quicker process for assessing drug particle size, which is especially useful in early-stage development, helping device manufacturers and drug companies shorten development timelines.

Originally used for rough particle size estimates, AIM has evolved to be included in FDA submissions and ongoing quality control testing. It allows for effective mass balance exercises while reducing the time and effort required for analysis.

Abbreviated impactors such as the Fast Screening Impactor (FSI), Fast Screening Andersen (FSA), and Reduced Next Generation Impactor (rNGI) are popular tools that deliver results transferable to full-resolution devices, like the Andersen Impactor, making AIM an essential tool for streamlined inhalation product development and testing.